GoodRx Launches New Programs to Expand Access to Weight Loss Medications
Table of Contents
GoodRx’s initiatives aim to lower the cost of popular GLP-1 drugs like Ozempic and wegovy,offering a telemedicine subscription and discounted cash prices.
GoodRx is taking significant steps to address the growing demand and high cost of GLP-1 medications used for weight loss, unveiling two major programs designed to increase accessibility for patients. The company announced the launch of GoodRx for Weight Loss, a direct-to-consumer telemedicine subscription, alongside a partnership with Novo nordisk to offer a $199 monthly cash price for Ozempic® and Wegovy® injection pens.
Simplifying the GLP-1 Treatment Journey with Telemedicine
The new GoodRx for Weight Loss subscription is designed to streamline the entire process of obtaining and managing GLP-1 treatment, from the initial consultation with a healthcare provider to prescription fulfillment. The program prioritizes affordability and trust by exclusively offering FDA-approved GLP-1 medications, explicitly rejecting the use of unproven compounded alternatives.
Key features of the subscription include:
- Virtual Consultations: Patients will connect with licensed healthcare providers to determine their eligibility for GLP-1 treatments and receive a prescription.
- Obvious Pricing: The program ensures upfront cost clarity, eliminating hidden fees.
- Flexible Fulfillment: Options include in-store pickup at pharmacies nationwide for Wegovy or Zepbound® (tirzepatide), and convenient home delivery of the Zepbound vial formulation through LillyDirect.
- Ongoing Clinical Support: Continuous support will be provided to track patient progress, manage potential side effects, and adjust treatment plans as needed.
the subscription is currently available at an introductory rate of $39 per month through January 2026,after which the standard monthly price will be $119.
Significant Savings on Ozempic and Wegovy through Novo Nordisk Partnership
Addressing the financial barrier to entry for many patients, GoodRx is collaborating with Novo Nordisk to provide ample savings on two widely prescribed medications. First-time GoodRx users who are paying out-of-pocket can now access Ozempic® (semaglutide) and Wegovy® (semaglutide) injection pens for an introductory price of $199 per month.
This discounted price is applicable to the two lowest doses – 0.25 mg and 0.5 mg – and is valid for the first two fills. Following the initial two-month period, patients will transition to a standard monthly price of $349. The reduced prices are intended to make these treatments more accessible to eligible patients at pharmacies across the country.
“GoodRx is scaling a consumer-first model for affordable GLP-1 treatment,” said Wendy Barnes, President and CEO of GoodRx, in a company release. “We’re committed to connecting consumers with FDA-approved GLP-1 medications backed by science and safety, not compounded alternatives that fall short of those standards. By uniting nationwide pharmacy integration,home delivery capabilities,and transparent pricing in one seamless experience,GoodRx is creating a higher standard for affordability and trust in weight loss care.”
These initiatives represent a significant effort to democratize access to perhaps life-changing medications, offering a more affordable and manageable path for individuals seeking GLP-1 treatment options.
– GLP-1 medications originally gained approval for treating type 2 diabetes. Their weight loss benefits were later discovered during clinical trials and led to expanded FDA approvals.
– Check GoodRx’s website or app for the moast up-to-date pricing and eligibility requirements for both the subscription service and the Novo Nordisk partnership.
– Will insurance cover GoodRx’s weight loss programs? Coverage varies; check with your insurance provider for specific details regarding reimbursement.
